Ron Lanton, Partner, Lanton Law, weighs in on the potential international trade, pricing, and access implications of tying US drug costs to those in other developed countries under the Most Favored ...

In order to succeed in today’s outcomes-driven healthcare landscape, pharmaceutical companies must move from traditional ...